In individuals with hemophilia A and persistent inhibitors, immune tolerance induction (ITI) consisting of frequent high-dose FVIII infusions remains the primary strategy for inhibitor eradication and restoration of FVIII tolerance. The gene discussed is F8; the disease is hemophilia A.